Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating expenses:        
Research and development $ (2,714) $ (5,043) $ (5,165) $ (14,786)
General and administrative (4,273) (3,210) (7,669) (6,361)
Total operating expenses (6,987) (8,253) (12,834) (21,147)
Operating loss (6,987) (8,253) (12,834) (21,147)
Interest expense, net (980) (4,075) (3,932) (6,671)
Financing transaction costs       (2,130)
Adjustments to fair value of derivatives 15,794 (12) (74,309) 1,667
Other income / (expense), net 93 (3) 134 (41)
Total other income / (expense), net 14,907 (4,090) (78,107) (7,175)
Income / (loss) before income taxes 7,920 (12,343) (90,941) (28,322)
Income tax expense (122) (178) (182) (299)
Net income / (loss) and comprehensive income / (loss) 7,798 (12,521) (91,123) (28,621)
Net income / (loss) attributable to ordinary shareholders $ 7,798 $ (12,521) $ (91,123) $ (28,621)
Net income / (loss) per share attributable to ordinary shareholders – basic $ 0.04 $ (0.80) $ (0.63) $ (1.87)
Net income / (loss) per share attributable to ordinary shareholders – diluted $ 0.04 $ (0.80) $ (0.63) $ (1.87)
Weighted average ordinary shares outstanding – basic 180,017,313 15,614,767 144,608,227 15,295,141
Weighted average ordinary shares outstanding – diluted 204,600,645 15,614,767 144,608,227 15,295,141